Pleiotropic Effects of Substitutions of a Highly Conserved Leucine in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with Respect to Constitutive Activation and Hormone Responsiveness
Hiromitsu Shinozaki,
Francesca Fanelli,
Xuebo Liu,
Julie Jaquette,
Kazuto Nakamura and
Deborah L. Segaloff
Department of Physiology and Biophysics (H.S., X.L., J.B., D.L.S.)
and Department of Pharmacology (K.N.) The University of
Iowa Iowa City, Iowa 52242
Department of Chemistry
(F.F.) University of Modena and Reggio Emilia 41100 Modena,
Italy
 |
ABSTRACT
|
---|
It has been shown previously that a naturally
occurring mutation of the human LH/CG receptor (hLHR), which replaces
L457 in helix III with arginine, results in a receptor that
constitutively elevates basal cAMP but does not respond to human CG
(hCG) with further cAMP production. In the present study, substitutions
of L457 with several amino acids were examined. The constitutive
activation of cAMP production was observed only when L457 was replaced
with a positively charged residue. Although constitutive activation of
the inositol phosphate pathway could not be detected when measuring
inositol phosphate production, the use of a more sensitive reporter
gene assay for protein kinase C activation revealed the constitutive
activation of this pathway by the R- and K-substituted mutants.
Therefore, L457 of the hLHR plays a key role in stabilizing the
receptor in an inactive conformation. Molecular modeling shows that the
insertion of R, K, or H at position 457 triggers the receptor
transition toward an active state due to the proximity of an anionic
amino acid, D578, in helix VI. These substitutions cause perturbations
in helix III-helix VI and helix III-helix VII interactions that
culminate in the opening of a solvent-accessible site in the
cytosolic domains potentially involved in Gs recognition.
Interestingly, L457R was completely unresponsive and the K- and
H-substituted L457 hLHR mutants were significantly blunted in their
cAMP responses to hCG stimulation. Cells expressing L457R were also
unresponsive to hCG with regards to increased inositol phosphate
production. Other substitutions of L457 were identified, though, that
selectively permit the hormonal stimulation of only one of the two
signaling pathways. These results suggest a pivotal role for L457 in
hormone-stimulated signal transduction by the hLHR.
 |
INTRODUCTION
|
---|
The LH/CG receptor (LHR) is a G protein-coupled receptor (GPCR)
that plays a central role in reproductive physiology in both males and
females. The carboxyl half of the receptor is composed of seven
transmembrane (TM) helices connected by extracellular and intracellular
loops. The amino acid sequences of the predicted TM regions of the LHR
define it as a member of the large subfamily of rhodopsin-like GPCRs
(1). Like the closely related FSH receptor (FSHR) and TSH receptor
(TSHR), the LHR contains a relatively large amino-terminal
extracellular domain composed of multiple leucine-rich repeats (2, 3).
Leucine-rich repeats have been suggested to be involved in
protein-protein interactions (4, 5) and, indeed, it has been shown that
the high-affinity binding of hormones to the LHR, FSHR, and TSHR occur
via interactions with the extracellular domain (6, 7, 8, 9, 10, 11, 12). The
interactions of LH or hCG with the extracellular domain of the LHR then
presumably allow regions of the extracellular domain and/or hormone to
interact with the carboxyl half of the receptor in a manner that
stabilizes it in an active conformation (13, 14, 15). The LHR is known to
stimulate both the cAMP and the inositol phosphate second messenger
pathways (16, 17, 18, 19, 20). However, the activation of the inositol phosphate
pathway is observed only under conditions of high LHR numbers and
relatively high concentrations of hormone (18, 19). Whereas the
physiological contributions of LH/CG-stimulated cAMP in male and female
physiology are well established, the role of LH/CG-stimulated inositol
phosphate production is less clear.
The LHR present in the ovaries and testes binds either LH, produced by
the pituitary in postpubertal men and women, or the structurally
related hormone hCG, produced by the placenta of pregnant females, and
serves to regulate several key aspects of reproductive physiology and
developmental biology. In nonpregnant females, LH is involved in the
production of ovarian steroid hormones. The monthly midcycle surge of
LH also mediates ovarian follicular maturation and ovulation. In males,
the role of the LHR comes into play as early as fetal development.
During that time, the LHR present on Leydig cells of the testes binds
maternal hCG and stimulates the production of testosterone. Under the
actions of this androgen, the external genitalia of the fetus
differentiate into the male phenotype. After birth, the male is no
longer exposed to maternal hCG and is not exposed to LH until the time
of puberty. When puberty is reached, the hypothalamic-pituitary-gonadal
axis matures, and the elevated levels of LH then stimulate testosterone
production.
In recent years many naturally occurring loss-of-function and
gain-of-function mutations of the hLHR have been described (see Ref. 21
for a review). The gain-of-function mutations have been identified in
young boys with gonadotropin-independent precocious puberty, also
called "testotoxicosis." These individuals have been found to have
heterozygous mutations of the hLHR that cause it to constitutively
elevate basal cAMP levels. Therefore, in the face of prepubertal low
levels of pituitary LH, the testes of these boys constitutively secrete
testosterone, which then elicits the physiological changes accompanying
male puberty.
At this writing, 14 independent naturally occurring activating
mutations of the human (h)LHR have been identified (21, 22). All
of them have been identified in the carboxyl half of the receptor, with
many of them clustering in TM VI. This may reflect the importance of
this region of the hLHR in activating Gs (23, 24). It should also be
pointed out, however, that many earlier studies focused only on this
portion of the gene when searching for mutations. Indeed, as more
recent studies have sequenced the entire carboxyl half of the gene from
individuals thought to have activating hLHR mutations, substitutions
causing activation have been found in other helices as well.
We had previously reported the identification of an activating mutation
of the hLHR in TM III (25). This mutation results in the substitution
of an arginine in place of a highly conserved leucine. This leucine,
designated Leu III.18 per the Baldwin model of the GPCR TM helices
(26), is conserved in
70% of rhodopsin-like GPCRs. As one would
predict, cells transfected with the L457R mutant exhibited elevated
levels of basal cAMP. The basal levels of cAMP in cells expressing the
activating mutant, while greater than the basal levels of cells
expressing the wild-type hLHR, were less than the maximal levels of
cAMP observed in cells expressing the wild-type hLHR incubated with a
saturating concentration of hormone. However, whereas cells expressing
most activating mutants will respond with a further increase in cAMP
when challenged with hormone, cells expressing L457K are completely
unresponsive to further cAMP stimulation by hCG addition (25).
The present studies were undertaken to determine the molecular basis
for the constitutive activation of the cAMP pathway by hLHR(L457R) and
its inability to respond further to hormone. Results presented support
the model that Leu III.18 plays a conserved role in stabilizing the
inactive state of GPCRs, but that constitutive activity requires both
the disruption of the bonds stabilized by this conserved leucine and
the introduction of specific residues that promote interhelical
interactions stabilizing the active state of the receptor.
 |
RESULTS
|
---|
Previous studies had shown that substitution of Leu III.18 (L457)
of the hLHR with arginine results in a receptor that constitutively
stimulates the production of cAMP, but is unresponsive to further cAMP
production by hCG addition (25). To determine the mechanisms underlying
this peculiar phenotype, we studied additional mutants of the hLHR in
which L457 was substituted with basically charged residues (arginine,
lysine, or histidine), with an uncharged residue (alanine), or with a
negatively charged residue (aspartate).
When transfected with maximal amounts of plasmid, the levels of cell
surface receptors for L457K were higher than those of wild-type
receptor. Those for L457R, L457H, and L457A were similar to the
wild-type receptor, and those of L457D were much lower (Table 1
). Since both basal and
hormone-stimulated second messenger production can be dependent upon
cell surface receptor number (27, 28), a correction for receptor
expression must be taken into account. Because second messenger
production was not linear with respect to receptor number over the
range of receptor numbers in these experiments, it was not possible to
correct a given response by dividing by the cell surface binding.
Instead, we used an approach previously described (25, 29, 30) in which
we deliberately varied the plasmid concentrations used in the
transfections to yield cells with similar (no more than 2-fold
different) numbers of cell surface receptors. In our experience, a
2-fold difference in receptor number (within the range of expression
observed in these experiments) has not been of consequence. Therefore,
although the absolute numbers of cell surface receptors varied from
experiment to experiment, a given mutant was always compared within the
same experiment to a wild-type control with matched numbers of cell
surface receptors.
As shown in Table 2
, cells expressing hLHR(L457R) exhibit approximately
10-fold elevation in basal cAMP levels as compared with cells
expressing similar numbers of wild-type receptors, consistent with the
constitutive activation of this signaling pathway (31). Cells
expressing L457K also exhibited markedly increased basal levels of
cAMP, suggesting that the introduction of a positive charge at codon
457 is required for constitutive activation of the cAMP pathway by the
hLHR. Consistent with this conclusion is the observation that L457H
cells showed slightly elevated levels of basal cAMP and that the basal
levels of cAMP in L457A and L457D cells were not at all elevated.
View this table:
[in this window]
[in a new window]
|
Table 2. Solvent-Accessible Surface (SAS) of the
Cytosolic Extensions of Helices III and VI of hLHR(wt) and
L457-Substituted Mutants Correlates with Observed Constitutive
Activation
|
|
To determine whether any of the L457-substituted hLHR mutants
constitutively activated the inositol phosphate pathway, we measured
basal inositol phosphate levels in cells expressing the wild-type hLHR
and each of the mutants. We found no detectable increases in basal
inositol phosphates in cells expressing any of the mutants (Table 3
). It has been shown, however, that the
measurement of basal inositol phosphate levels does not always reveal
constitutive activation of this pathway due to the relatively poor
sensitivity of this assay (32). Rather, constitutive activation of this
pathway can more readily be observed using a more sensitive reporter
gene assay indicative of C kinase activation (32). Using the C
kinase-responsive reporter gene assay it was possible to detect small,
but reproducible, increases in basal C kinase activity in cells
expressing the K- and R-substituted mutants. Cells expressing L457K
exhibited approximately 20% increase in activity and cells expressing
L457R exhibited about 90% increase in activity. These results suggest
that substitutions of hLHR(L457) with positively charged residues cause
constitutive activation of both the cAMP and the inositol phosphate
pathways.
View this table:
[in this window]
[in a new window]
|
Table 3. Basal Activation of the Inositol Phosphate/C
Kinase Pathway in Cells Expressing hLHR(wt) or L457-Substituted
Mutants
|
|
Recently, a molecular modeling approach has been used to describe hLHR
mutants that constitutively activate the cAMP pathway (33). Comparative
molecular dynamics (MD) simulations were carried out on most of the
naturally occurring activating and inactivating mutations discovered
thus far by using an ab initio model of the hLHR (33). The
constitutively active mutants were all predicted to have an augmented
solvent exposure of the cytosolic domains. A good marker of this
structural feature was found to be the solvent-accessible surface of
W465 (SASW465). This theoretical descriptor was
able to account for the structural differences between inactive and
active hLHR forms, being lower than 32 Å2 in
inactive mutants and greater than 32 Å2 in
constitutively active mutants. SASW465 values
greater than 32 Å2 were found to mark the
opening of a crevice between the second and third intracellular loops
(i2 and i3), respectively. The same computational approach has been
applied to the molecular modeling of the L457 mutants presented in this
work. The comparison between computer simulations and experiments
strengthens the ability of SASW465 to predict the
functional behavior of the hLHR mutants. In fact, the average minimized
structures of the R, K, and H constitutively active mutants are
characterized by SASW465 values above the
threshold and an opening in the crevice between i2 an i3. The D and A
mutants, which do not constitutively activate Gs, are characterized by
the absence of an open crevice between i2 and i3. However, for the
L457A mutant, the theoretical descriptor
SASW465 does not
properly describe the degree of solvent exposure of the cytosolic
extensions of helices III, V, and VI. In fact, although the
SAS(W465) value for the L457A mutant is above
30.0 Å2, the L457A mutant does not exhibit an
increased cytosolic exposure of helices III and VI. In the attempt to
improve the predictive power of the theoretical descriptor, we
determined that a composite SAS computed over a greater number of
residues in the cytosolic extensions of helices III and VI facing the
core of the helix bundle (i.e. W465 and I468 in helix III as
well as I567 and K570 in helix VI) more effectively differentiates
between the active and inactive forms of the L457-substituted mutants.
The composite SAS is below 100 Å2 in the
wild-type hLHR and the L457D and L457A mutants, whereas it is greater
than 100 Å2 in the L457H, L457K, and L457R
constitutively active mutants (Table 2
).
Our data show that substitution of L467R in TM III of the hLHR with a
positively charged residue stabilizes the hLHR in a conformation that
can constitutively activate both the cAMP and the inositol phosphate
pathways. The following experiments were performed to examine what
effects substitutions of this highly conserved leucine residue have on
hormone-stimulated second messenger production. Looking at the hCG
responsiveness of the wild-type hLHR and the L457-substituted mutants,
there was little (L457K, L457H) or no (L457R) hCG-mediated stimulation
of cAMP in the mutants with a positively charged residue at III.18
(Fig. 1A
). This is not because the basal
levels of cAMP induced by these mutants were already maximal. As shown
in Fig. 1B
, the Rmax values of L457R, L457K, and L457H were about
one-half that of cells expressing the same numbers of wild-type hLHR.
On the other hand, the hCG responsiveness of cells expressing the
alanine or aspartate-substituted mutants was completely normal (Fig. 1
, A and B). Therefore, with regard to the cAMP second messenger pathway,
there appears to be a correlation between the introduction of a
positive charge at III.18, the induction of constitutive activity, and
reduced hCG-mediated stimulation of cAMP.

View larger version (39K):
[in this window]
[in a new window]
|
Figure 1. Replacement of hLHR(L457R) with Positively Charged
Residues Attenuates hCG-Stimulated cAMP Accumulation in Intact Cells
HEK293 cells were transiently transfected with the indicated hLHR
construct to generate cells with matching numbers of cell surface
receptors as described in Materials and Methods. Panel
A, cAMP in response to a saturating concentration of hCG
is presented as the ratio of Rmax to basal cAMP (i.e.
the fold stimulation) in cells expressing a given receptor. The
dashed line indicates the fold stimulation of the
wild-type hLHR. Panel B, cAMP in response to a saturating concentration
of hCG is presented as the Rmax in cells expressing a mutant relative
to the Rmax in matched cells expressing the wild-type hLHR. Therefore,
the Rmax of wild-type hLHR-expressing cells is defined as 1.0 and is
shown by the dashed line.
|
|
The following experiments were performed to determine the basis for the
lack of stimulation of cAMP production by hCG in cells expressing the
L457R, L457K, or L457H. One possibility considered was that these
mutants might have a lower binding affinity for hCG. However, as shown
in Table 4
, binding assays to intact
cells revealed similar binding affinities for all the L457-substituted
mutants as compared with the wild-type hLHR. Another possibility
considered was whether the R, K, and H mutants might internalize hCG
more rapidly. If so, this may serve to terminate the signaling of cAMP
production by the hormone-occupied receptor. As shown in Fig. 2
, we found that cells expressing L457R,
L457K, or L457H do internalize hCG at a faster rate than cells
expressing the wild-type hLHR. In contrast, cells expressing L457A or
L457D internalize hCG at a slower rate than cells expressing the
wild-type receptor.

View larger version (41K):
[in this window]
[in a new window]
|
Figure 2. Substitution of hLHR(L457) with Positively Charged
Residues Causes the Mutant Receptors to Internalize hCG at a Faster
Rate
293 cells were transiently transfected with either the wild-type (wt)
hLHR or L457 mutants substituted with arginine (R), lysine (K), alanine
(A), or aspartic acid (D). The internalization of 125I-hCG
was measured as described in Materials and Methods. Data
are presented as an internalization index, which, under the conditions
used, is proportional to the rate of internalization. Data shown are
the mean ± range of two independent experiments. The
internalization index of cells expressing the wild-type hLHR is noted
with a dashed line.
|
|
If the increased rate of hCG internalization by the R, K, and
H-substituted L457 hLHR mutants was the cause of the attenuated
hCG-stimulated cAMP production of cells expressing these receptors,
then one would predict that membranes isolated from these cells would
respond normally to hCG with increased adenylyl cyclase activity (since
the membranes cannot internalize hCG). Therefore, membranes were
isolated from cells expressing either the wild-type hLHR, or the R, K,
or H-substituted L457 mutants and assayed for both basal and
hCG-stimulated adenylyl cyclase activity (Fig. 3
). The basal adenylyl cyclase activity
of L457R membranes was elevated more than 2-fold above that of
wild-type hLHR membranes. The basal activities of L457K and L457H
membranes, however, showed little or no increase though. With regard to
the hCG-stimulated cyclase activity in membranes containing the
L457R-substituted hLHR mutants, the maximal response of L457K and L457H
membranes in response to hCG was similar to that of the wild-type hLHR
membranes (Fig. 3
). However, L457R membranes showed no detectable
increase in adenylyl cyclase activity in response to hCG. These results
suggest that the increased rate of internalization of hCG by L457R
cells cannot account for the inability of cells expressing this mutant
to respond to hCG with increased cAMP production. Rather, there must be
a structural modification of the L457R mutant per se that
impairs its ability to stimulate adenylyl cyclase when occupied by
agonist.

View larger version (41K):
[in this window]
[in a new window]
|
Figure 3. Adenylyl Cyclase Assays Reveal Different Mechanisms
Underlying the Lack of hCG Stimulation of cAMP by hLHR(L457) Mutants
Substituted with Positively Charged Residues
293 cells were transiently transfected with either the wild-type (wt)
hLHR or L457 mutants substituted with arginine (R), lysine (K), alanine
(A), or aspartic acid (D) to match receptor numbers as described in
Materials and Methods. Membranes were isolated and
assayed for basal and hCG-stimulated adenylyl cyclase activity as
described in Materials and Methods. Data shown are the
mean ± SEM of four independent experiments.
|
|
Interestingly, cells expressing L457R, which do not respond to hCG with
increased cAMP production, also do not respond to hCG with increased
inositol phosphate production (Fig. 4
).
The L457R mutant, however, is the only mutant in which there is a
correlation between hCG-stimulated cAMP and hCG-stimulated inositol
phosphate responses. Cells expressing L457H responded to hCG with as
great a fold stimulation of inositol phosphates as cells expressing the
wild-type receptor (Fig. 4
). This, one should note, is in contrast to
hCG-stimulated cAMP production, which is blunted in the L457H cells
(cf. Fig. 1
). Similarly, cells expressing L457K responded to hCG with
increased inositol phosphate production (albeit not as robustly as
wild-type cells or L457R cells; see Fig. 4
), whereas they showed little
hCG stimulation of cAMP production (cf. Fig. 1
). Cells expressing L457A
also exhibited a moderate response to hCG with regard to inositol
phosphate production (Fig. 4
), in contrast to a fully normal response
with regard to cAMP production (cf. Fig. 1
). Interestingly, L457D cells
did not show any detectable increases in inositol phosphates in
response to hCG (Fig. 4
) in spite of their responding normally to hCG
with increased cAMP (cf. Fig. 1
). Taken altogether, the data presented
in Figs. 1
and 4
demonstrate that substitution of L457 of the hLHR with
aspartate causes the receptor to respond to hCG with the selective
stimulation of the cAMP pathway, whereas substitution with histidine
causes the receptor to respond to hCG with the selective stimulation of
the inositol phosphate pathway.

View larger version (45K):
[in this window]
[in a new window]
|
Figure 4. Effects of Substitutions of hLHR(L457) on
hCG-Stimulated Inositol Phosphate Production
HEK293 cells were transiently transfected with the indicated hLHR
construct to generate cells with matching numbers of cell surface
receptors as described in Materials and Methods. Panel
A, The data for basal inositol phosphate production are presented as
the ratio of basal inositol phosphates in cells expressing a mutant
relative to basal inositol phosphates in matched cells expressing the
wild-type hLHR. Therefore, basal inositol phosphates in wild-type
hLHR-expressing cells are defined as 1.0 and are shown by the
dashed line. Panel B, Inositol phosphates in response to
a saturating concentration of hCG are presented as the ratio of Rmax to
basal inositol phosphates (i.e. the fold stimulation) in
cells expressing a given receptor. The dashed line
indicates the fold stimulation of the wild-type hLHR.
|
|
 |
DISCUSSION
|
---|
Previous studies from our laboratory have identified an activating
mutation of the hLHR in a young boy with gonadotropin-independent
precocious puberty that resulted in the substitution of L457 with
arginine (25). As with other activating mutations of the hLHR, cells
expressing this mutant receptor exhibited elevated levels of basal cAMP
when compared with cells expressing equivalent numbers of cell surface
wild-type hLHR. Compared with other activating hLHR mutations, however,
this L457R mutation causes a relatively higher fold increase in basal
cAMP than most other mutants. Another interesting feature of this
mutant is that, in spite of it causing constitutive activation of the
cAMP pathway, it does not respond to hCG with further increases in cAMP
even though the levels of basal cAMP are not as great as those in cells
expressing the wild-type receptor that have been stimulated with
hormone.
The revised ternary model for GPCR activation predicts that a given
receptor exists in the plasma membrane in an equilibrium between
inactive R state and an active R* state (see Ref. 1 for a review). The
binding of agonist shifts the equilibrium toward the active state,
thereby stabilizing this pool of receptor. Constitutively activating
mutations of GPCRs are thought to also stabilize the active state of
the receptor. Whether a mutation-induced R* conformation is identical
to the agonist-induced R* conformation is not yet clear. This issue is
further compounded by observations suggesting that there may be
multiple activated states for a given GPCR, some intermediary in nature
(designated R') (1, 34, 35, 36). As such, any one of a number of
intermediary R' or fully active R* states may in turn be stabilized by
a given mutation causing constitutive activation.
Leucine 457 of the hLHR represents a highly conserved leucine in TM III
in GPCRs (26). The studies presented herein show that substitution of
L457R of the hLHR with arginine, lysine, or histidine, but not with
alanine or aspartate, causes the receptor to constitutively activate
the cAMP pathway, with the greatest activation observed with an R
substitution and the least with the H substitution. We could not detect
any elevations in inositol phosphate levels in cells expressing these
mutants. However, since it was previously shown by Jinsi-Parimoo and
Gershengorn (32) that whereas constitutive activation of the inositol
phosphate/C kinase pathway by isoforms of the TRH receptor could not be
detected by classical measurements of inositol phosphate production but
could be readily discerned using a more sensitive C kinase-responsive
reporter gene assay, we also examined activation of this pathway using
the same C kinase-responsive reporter gene construct. Under these
conditions, modest (20% and 90%) increases in basal C kinase activity
were observed for cells expressing L457K and L457R, respectively.
Although reports differ in the identification of G proteins mediating
the stimulation of the inositol phosphate pathway by the LHR (16, 20),
it is clear that Gs is not involved and it is likely that Gi is
involved. Therefore, our results suggest that substitutions of L457 of
the hLHR with positively charged residues stabilize the receptor in a
conformation capable of constitutively activating both Gs and
Gi.
Recently, a theoretical model for mutation-induced constitutive
activation of the hLHR with regard to stimulation of cAMP production
via Gs activation was proposed (33). The comparative MD analyses showed
that the hLHR sites susceptible to activating mutations lie mainly at
interhelical positions close to highly conserved amino acids.
Constitutively active hLHR mutants were characterized by the opening of
a crevice between i2 and i3 that allows solvent exposure of the
intracellular extensions of helices III and VI. This presumably allows
greater accessibility of Gs to the regions of the hLHR involved in G
protein activation. In agreement with the conclusions of the modeling
studies, a peptide corresponding to the juxtacytoplasmic region of
helix VI has been shown to be able to activate Gs directly (23, 24).
Similar computer simulations on the L457-substitutions of the hLHR
predict conformations of the R, K, and H-substituted mutants as being
active (Table 1
) and further suggest a mechanism underlying their
constitutive activation. According to the theoretical model, L457 is
close to D578 in helix IV (VI:16) as well as to N615 and N619 in helix
VII (VII:17), where N619 belongs to the highly conserved NPXXY motif.
The introduction of a positively charged amino acid at position 457
generates an attractive effect on D458 (VI:16), thus inducing
perturbations in helix III-helix VI and helix III-helix VII interaction
patterns. The local perturbations introduced by these amino acid
replacements culminate in the opening of a solvent-accessible site in
the cytosolic domains potentially involved in Gs recognition.
To provide further insight into the structural features of the L457
mutants, a new hLHR model has been built (F. Fanelli, manuscript in
preparation) by comparative modeling using the recently determined
crystal structure of rhodopsin (37). Preliminary computer simulations
on the wild-type and the L457 mutants with this homology model agree
with the ab initio model in that positively charged amino
acids in position L457 are predicted to induce perturbations in helix
III-helix VI and helix III-helix VII interactions. As shown in Fig. 5
, these rearrangements result from the
formation of new interactions between the replacement amino acid at
III.18, on the one hand, and D578 (VI:16), N615 (VII:13), and N619
(VII:17), on the other. Similarly to the ab initio model,
the homology model predicts that the local perturbations induced by
these activating mutations enhance the solvent exposure of the
cytosolic extensions of helices III and VI.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 5. Structural Environment of the Mutated Position 457
(III.18) in the Homology hLHR Model
Details of the amino acids that constitute the environment of position
457 are shown. The receptor is seen in a direction parallel to the
membrane surface. Residues in helices III, VI, and VII are colored in
green, sky blue, and violet,
respectively.
|
|
It is notable that, thus far, five GPCRs, the hLHR, hFSHR (30), human
ß2-adrenergic receptor
(hß2-AR) (30), rat m1
muscarinic acetylcholine receptor (rm1AchR) (38),
and the C5a receptor (39), have been shown to be rendered
constitutively active upon substitution of Leu III.18, suggesting that
this residue may play a conserved role in stabilizing the inactive
state of GPCRs. Notably, there is variability among these five GPCRs
with respect to which amino acid replacements of Leu III.18 cause
constitutive activation. The rm1AchR and C5a
receptor Leu III.18 substitutions were made in the context of alanine
scanning mutagenesis where alanine substitutions were found to cause
constitutive activation. For the hFSHR, hLHR, and
hß2-AR, substitutions of Leu III.18 with
arginine, lysine, histidine, alanine, and aspartate were examined. In
terms of the cAMP pathway, constitutive activation of the hLHR was
observed with arginine, lysine, or histidine substitutions (Table 1
),
but constitutive activation of the hFSH was observed only with an
arginine substitution (30). Constitutive activation of the
hß2-AR was unrelated to the insertion of
positive residues since arginine, lysine, or alanine caused activation
(in this case the histidine replacement was not examined and an
aspartate substitution caused lack of cell surface expression) (30).
The mutagenesis studies of Leu III.18 in these five GPCRs further
complement other studies suggesting that helix III may serve as a
critical component of the switch for GPCR activation (1, 39, 40, 41, 42, 43).
The wild-type LHR can activate both the cAMP and the inositol phosphate
second messenger pathways (18, 44). Our studies show that substitution
of L457 with arginine renders the hLHR unable to stimulate either the
cAMP or the inositol phosphate pathway. However, the other hLHR(L457)
substitutions examined herein showed no correlation between an
attenuation of hCG-stimulated cAMP and hCG-stimulated inositol
phosphate production. Notably, certain substitutions of L457 were found
to confer selectivity with respect to the second messenger pathway
stimulated by hCG occupancy. For example, in response to hCG, a
histidine substitution of L457 causes activation of the inositol
phosphate pathway, but not the cAMP pathway. In contrast, an aspartate
substitution of L457 causes hCG-stimulated activation of the cAMP
pathway, but not the inositol phosphate pathway. Previous studies by Ji
and colleagues (45) showed that certain substitutions of K583 in the
third extracellular loop of the rat LHR (rLHR) caused the receptor to
respond to hCG with increased inositol phosphate production, but not
cAMP production, suggesting a divergence in the signaling by the LHR to
these two pathways. The present studies now show that not only can
certain substitutions of the LHR cause selective agonist-induced
activation of the inositol phosphate pathway, but also others can
confer selective agonist-induced activation of the cAMP pathway. The
ability of substitutions of L457 of the hLHR to abrogate the agonist
stimulation of one or both second messenger pathways suggests a key
role for this residue in mediating the hormonal activation of the
hLHR.
The mutants in which a positively charged R, K, or H was inserted at
position 457 were both constitutively active and unresponsive to
further hormonal stimulation of cAMP production. It should be noted
that although these mutants caused basal levels of cAMP to be elevated,
they were not elevated to the same magnitude as cells expressing the
wild-type hLHR incubated with a saturating concentration of hormone.
Therefore, the lack of hormonal responsiveness is not simply a
consequence of the mutants causing maximal elevation of cAMP under
basal conditions. Indeed, these observations suggest that the active
states of constitutively active hLHR mutants are probably intermediate
between the inactive state and the fully activated state stabilized by
hormone. Further studies to explore the potential causes of the lack of
hCG-stimulated cAMP production by these mutants revealed several
interesting features. First, the lack of hCG responsiveness is not due
to a decreased binding affinity of the mutants for hCG since the
binding affinities of all were normal. Second, it was observed that
cells expressing the R, K, and H-substituted L457 mutants all
internalized hCG at a significantly higher rate than the wild-type
hLHR. Since the internalized hormone-occupied LHR no longer
stimulates cAMP production (46), the increased rate of internalization
by these mutants could conceivably account for their decreased hCG
responsiveness if internalization was the primary means of terminating
the signaling to Gs. Indeed, when the rat LHR (rLHR) containing a
mutation of Leu III.18 to arginine was examined, it was found to
constitutively elevate basal cAMP production, to be unresponsive to hCG
with regard to further cAMP increases, and to internalize hCG at a
faster rate than the wild-type rLHR (47). When isolated membranes
(which, by definition, are devoid of any internalization activity)
derived from cells expressing either the wild-type or the mutant rLHR
were examined for basal and hCG-stimulated cAMP production, it was
found that the membranes with mutant rLHR had an elevated basal
adenylyl cyclase activity (consistent with the mutants constitutive
activity), but responded similarly to wild-type rLHR membranes when
incubated with hCG (47). These observations supported the hypothesis
that the increased internalization of hCG by the rLHR mutant was
responsible for the decreased ability of intact cells to respond to
further hormonal stimulation of the cAMP pathway.
We, therefore, also measured the basal and hCG-stimulated adenylyl
cyclase activity of membranes isolated from cells expressing the
wild-type hLHR or the mutants L457R, L457K, or L457H. Although all
three of these mutants, when analyzed in the context of intact cells,
exhibited constitutively elevated levels of basal cAMP, only L457R
showed a significant increase in basal cyclase activity above that of
wild-type hLHR membranes. It is likely, however, that the inability to
detect a measurable increase in the basal cyclase activity of the L457K
and L457H membranes is due to the reduced sensitivity of the
measurement of adenylyl cyclase activity in membranes as compared with
cAMP accumulation in intact cells. Since the constitutive activity (as
measured by cAMP accumulation) of the L457R mutant is greater than that
of the L467K and L457H mutants, its increased basal activity, as
determined in cyclase assays, may be more readily detectable. With
regard to agonist-stimulated cyclase activity, the L457K and L457H
membranes responded to hCG with increased adenylyl cyclase activity,
suggesting that the inability of these mutants to respond in the
context of intact cells is due to their more rapid internalization of
hCG and/or to other properties of the receptors that are present in
intact cells but not in membranes. However, the L457R membranes
remained completely unresponsive to hCG stimulation. These data
contrast with the observations reported on the rLHR containing the
comparable substitution and suggest a different mechanism underlying
the lack of hCG-stimulated cAMP production by cells expressing the
human vs. rat LHR in which Leu III.18 is substituted by
arginine.1 The lack of hCG
responsiveness of membranes containing hLHR(L457R) suggests that there
is a modification of this mutant that makes it unable to further
activate Gs when occupied by hCG. This change may reflect a structural
alteration or posttranslational modification of the receptor and/or an
association of the mutant receptor with other proteins. Whatever it may
be, it must be preserved during the preparation of membranes from
intact cells, and it prevents the receptor from undergoing the
transition from one of constitutively active in an intermediate state
to one of full activation stabilized by hormone.
It is intriguing to note that certain substitutions of Leu III.18 of
the hFSHR also cause this receptor to exhibit little or no response to
FSH with regard to further increases in cAMP (30). The demonstration
that certain substitutions of Leu III.18 of either the hLHR or hFSHR
cause decreases in hormone-stimulated activation of the cAMP pathway
and/or inositol phosphate pathway suggests that Leu III.18 plays a key
role in the transduction of hormone binding to the activation of G
proteins in these two related GPCRs. Because substitutions of Leu
III.18 of the hß2-AR receptor do not cause
decreased hormone responsiveness (30), it suggests that the role of Leu
III.18 in hormone-stimulated signal transduction may be restricted to
the gonadotropin receptors, or possibly the glycoprotein hormone
receptors if it is found to play a similar role in the closely related
TSHR.
 |
MATERIALS AND METHODS
|
---|
Hormones and Supplies
Highly purified hCG was generously provided by Dr. A. Parlow and
NIDDKs National Hormone and Pituitary Program. hCG was iodinated as
described previously (48). The crude preparation hCG used for
determining nonspecific binding in 125I-hCG
binding assays was obtained from Sigma (St. Louis, MO).
125I-cAMP and cell culture media were obtained
from the Iodination Core and the Media and Cell Production Core,
respectively, of the Diabetes and Endocrinology Research Center of the
University of Iowa. Tissue culture reagents were purchased from
Life Technologies, Inc. (Gaithersburg, MD) and
Corning, Inc. plasticwares were obtained from Fisher Scientific (Pittsburgh, PA).
Plasmids and Cells
The wild-type hLHR cDNA was kindly provided by Ares Advanced
Technology (Ares-Serono Group, Randolph, MA) and was subcloned into
pcDNA 3.1 (Invitrogen, San Diego, CA). Mutagenesis was
performed using the PCR overlap extension method (49, 50). The entire
region amplified by PCR, as well as the sites of ligation, were
sequenced to ensure that there were no unintended mutations of the
amplified cDNA. DNA sequencing was performed either within our
laboratory or by automated sequencing within the DNA Core of the
Diabetes and Endocrinology Research Center of the University of
Iowa.
Human embryonic 293 cells were obtained from the American Type Tissue
Collection (CRL 1573) and were maintained at 5%
CO2 in growth media consisting of high-glucose
DMEM containing 50 µg gentamicin, 10 mM HEPES, and 10%
newborn calf serum. For most experiments, cells were plated onto 35-mm
wells that had been precoated for 1 h with 0.1% gelatin in
calcium and magnesium-free PBS, pH 7.4. Cells were transiently
transfected when they were 5070% confluent following the protocol of
Chen and Okayama (51) except that the overnight precipitation was
performed in a 5% CO2 atmosphere. Differing
concentrations of plasmids were used to achieve the same cell surface
expression of a given mutant with the wild-type hLHR. Cells were then
washed with Waymouths MB752/1 media modified to contain 50 µg
gentamicin and 1 mg/ml BSA, after which fresh growth media were added.
The cells were used for experiments 24 h later.
Standardization of Cell Surface Receptor Numbers
In all experiments where the signaling properties of cells
expressing the hLHR(wt) were compared with cells expressing a mutant,
293 cells were transiently transfected with varying plasmid
concentrations such that within each experiment the number of cell
surface receptors for a given mutant was matched to cells expressing
comparable numbers of wild-type receptors. For each experiment the
ratio of 125I-hCG binding to cells expressing a
given mutant vs. the matched controls was determined, and
the experiment was used only if the ratio was within the range of
0.52.0 (i.e. within a 2-fold difference). For the
experiments measuring basal and hormone-stimulated cAMP production
(Table 1
and Fig. 1
) the means ± SEM of the
ratios of cell surface 125I-hCG binding to mutant
vs. wild-type hLHR-expressing cells were the following:
0.98 ± 0.16 for L457R (n = 8); 1.30 ± 0.18 for L457K
(n = 7); 0.92 ± 0.06 for L457H (n = 5); 1.19 ±
0.15 for L457A (n = 7); and 1.17 ± 0.15 for L457D (n =
9). For the experiments measuring basal (Table 2
) and hCG-stimulated
inositol phosphate production (Fig. 4
) the means ±
SEM of the ratios of cell surface
125I-hCG binding to mutant vs.
wild-type hLHR-expressing cells from three experiments were the
following: 0.81 ± 0.13 for L457R; 0.97 ± 0.30 for L457K;
0.1.18 ± 0.10 for L457H; 1.09 ± 0.19 for L457A; and
1.19 ± 0.24 for L457D. For the experiments measuring basal C
kinase-responsive luciferase activity (Table 2
) the means ±
SEM of the ratios of cell surface
125I-hCG binding to mutant vs.
wild-type hLHR-expressing cells were the following: 1.13 ± 0.11
for L457R (n = 9); 1.17 ± 0.12 for L457K (n = 11);
1.09 ± 0.12 for L457H (n = 11); 0.81 ± 0.08 for L457A
(n = 13); and 0.96 ± 0.014 for L457D (n = 6).
Therefore, the mutants were well matched to the controls and what
little deviation existed varied equally between mutants being expressed
2-fold higher vs.
2-fold lower density than the
wild-type hLHR.
Binding Assays to Intact Cells Expressing the hLHR
HEK 293 cells were plated onto gelatin-coated 35-mm wells and
transiently transfected as described above. On the day of the
experiment cells were placed on ice for 15 min and washed two times
with cold Waymouths MB752/1 containing 50 µg/ml gentamicin and 1
mg/ml BSA but no sodium bicarbonate. To determine the maximal binding
capacity, the cells were then incubated overnight at 4 C in the same
media containing a saturating concentration of
125I-hCG (500 ng/ml) with or without an excess of
unlabeled crude hCG (50 IU/ml). To determine the binding affinity, the
cells were incubated overnight at 4 C with increasing concentrations of
125I-hCG in the presence or absence of unlabeled
hCG. To terminate the assay, the cells were placed on ice. The contents
of each well were scraped into a plastic tube on ice and combined with
a 1 ml wash using cold HBSS modified to contain 50 µg/ml gentamicin
and 1 mg/ml BSA. The tubes were centrifuged at 4 C and the pellets
resuspended in 2 ml of the same wash media. After a second
centrifugation, the supernatants were aspirated and the pellets counted
in a
counter. Apparent binding affinities were determined as the
concentrations of 125I-hCG yielding half-maximal
binding as calculated by the DeltaGraph software Deltapoint (Monterey,
CA) when the data were fit to a sigmoidal equation (52).
Measurement of cAMP or Inositol Phosphate Production
The levels of cell surface receptors were measured within the
same experiment, and only those experiments in which the numbers of
cell surface receptors for wild-type vs. mutant receptors
differed by no more than 2-fold (see above) were used for second
messenger analyses. HEK 293 cells were plated on gelatin-coated 35-mm
wells and transfected as described above.
For cAMP determinations, cells were washed on the day of the experiment
twice with warm Waymouth MB752/1 media containing 50 µg/ml gentamicin
and 1 mg/ml BSA and placed in 1 ml of the same medium containing 0.5
mM isobutylmethylxanthine. After 15 min at 37 C, a
saturating concentration of hCG (100 ng/ml final concentration) or
buffer only was added, and the incubation was continued for 60 min at
37 C. The cells were then placed on ice, the media were aspirated, and
intracellular cAMP was extracted by the addition of 0.5 N
perchloric acid containing 180 µg/ml theophylline and then measured
by RIA. All determinations were performed in triplicate.
For inositol phosphate determinations, after the transfection, the
cells were washed with inositol-free DMEM containing 1% newborn calf
serum, 20 mM HEPES, and 50 µg/ml gentamicin and placed in
1 ml of the same media supplemented with 2 µCi/ml of
[2-3H]myo-inositol for 24 h. On the day of
the experiment, the cells were washed twice with warm Waymouth MB752/1
media modified to contain 50 µg/ml gentamicin, 1 mg/ml BSA, and 20
mM LiCl and then placed in this medium. After 15 min at 37
C, a saturating concentration of hCG (100 ng/ml final concentration) or
buffer only was added, and the incubation was continued for 60 min at
37 C. To terminate the assay, the cells were placed on ice, and cold
0.5 N perchloric acid was added to each well. The inositol
phosphates were extracted and assayed as described previously (53). All
determinations were performed in triplicate.
Measurement of C Kinase Activation Using a C Kinase-Responsive
Reporter Gene Assay
Plasmid containing a C kinase-responsive AP-1-fos-Luc reporter
gene construct was a gift from Dr. Marvin Gershengorn (NIDDK/NIH). HEK
293 cells were plated onto gelatin-coated 35-mm wells and transiently
cotransfected as described above with the C kinase-responsive reporter
gene construct, pcDNA3.1/neo containing the cDNA encoding the hLHR(wt)
or L457-substituted mutant, and empty pcDNA3.1/neo. The concentrations
of plasmid encoding the wild-type and mutant receptors were varied so
that a given mutant could be matched with a parallel set of cells
expressing the same level of wild-type receptor (see above). Because
luficerase activity was observed to be affected by the concentration of
pcDNA3.1/neo in the 293 cells, empty vector was utilized to adjust the
total concentration of pcDNA3.1/neo to be equal in all the cells.
Measurement of Adenylyl Cyclase Activity
The levels of cell surface receptors were measured within the
same experiment, and only those experiments in which the numbers of
cell surface receptors for wild-type vs. mutant receptors
differed by no more than 2-fold (see above) were used to determine
adenylyl cyclase activity. Membranes were prepared from 293 cells as
described previously (23). Adenylyl cyclase assays, based on the
procedure of Salomon (54), were performed as described previously (23)
except that GTP was not added to the assay. This change was
incorporated into the protocol because we observed a greater fold
stimulation of adenylyl cyclase activity in response to hCG when the
exogenous GTP was omitted.
Internalization of Receptor-Bound hCG
The hLHR-mediated internalization of hCG was measured following
the protocol described by Ascoli and colleagues (55). Transiently
transfected cells in 35-mm wells were preincubated in 1 ml Waymouth
MB752/1 media containing 1 mg/ml BSA and 20 mM HEPES, pH
7.4, for 30 min at 37C. 125I-hCG was then added
to give a final concentration of 40 ng/ml (with or without an excess of
unlabeled hCG to correct for nonspecific binding), and the cells were
incubated for 9 min at 37 C. The cells were then washed twice with cold
HBSS modified to contain 50 µg/ml gentamicin and 1 mg/ml BSA. The
surface-bound 125I-hCG was released by incubating
the cells on ice in 1 ml of cold 50 mM glycine, 150
mM NaCl, pH 3, for 4 min and rinsing them with 1 ml of the
acidic buffer (56). The acid washes from each well were combined and
counted to determine the amount of surface-bound
125I-hCG. Each well of acid-treated cells was
then solubilized in 0.5 N NaOH and counted to determine the
amount of internalized radioactivity. The results of these experiments
are expressed as an internalization index, which is defined as the
ratio of internalized vs. surface-bound
125I-hCG (57). Under the experimental conditions
used herein, the internalization index accurately reflects the rate of
internalization (55, 57). The rate of internalization is a first order
rate constant (55, 57) and is, therefore, independent of the
concentration of receptor or hormone. Therefore, for these experiments,
no effort was made to standardize the number of cell surface receptors
between the wild-type vs. mutant-expressing cells. In
addition, a subsaturating concentration of hormone was used to conserve
125I-hCG.
Molecular Modeling of the hLHR Mutants of L457
The initial structures of the L457 hLHR mutants were obtained by
replacing the target amino acid in the wild-type hLHR input structure
previously built after an ab initio approach (33). Energy
minimization and molecular dynamics simulations of the mutants were
performed using the program CHARMm (Molecular Simulations, Inc,
Waltham, MA) following the computational protocol previously described
(33).
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Mario Ascoli for thoughtful suggestions and careful
reading of the manuscript and Dr. Marvin Gershengorn for the
AP-1-fos-Luc reporter gene construct.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Deborah L. Segaloff, Ph.D., Department of Physiology and Biophysics, The University of Iowa, Iowa City, Iowa 52242. E-mail: deborah-segaloff{at}uiowa.edu
These studies were supported by NIH Grant HD-22196 (to D.L.S.). The
services and facilities of the University of Iowa Diabetes and
Endocrinology Research Center, supported by NIH Grant DK-25295,
are also acknowledged.
1 We have replicated the previously reported
results showing that membranes expressing the rLHR containing a Leu
III.18 to arginine substitution respond with increased adenylyl cyclase
activity using the same conditions as those used to assay hLHR(L457R).
Therefore, we conclude that the differences observed are indeed due to
differences between the two species of receptor and not to
methodological differences. 
Received for publication November 7, 2000.
Revision received February 21, 2001.
Accepted for publication March 19, 2001.
 |
REFERENCES
|
---|
-
Gether U 2000 Uncovering molecular mechanisms involved in
activation of G protein-coupled receptors. Endocr Rev 21:90113[Abstract/Free Full Text]
-
McFarland KC, Sprengel R, Phillips HS, Kohler M, Rosemblit N,
Nikolics K, Segaloff DL, Seeburg PH 1989 Lutropin-choriogonadotropin
receptor: an unusual member of the G protein-coupled receptor family.
Science 245:494499[Medline]
-
Hsu SY, Liang S-G, Hsueh AJW 1998 Characterization of two LGR
genes homologous to gonadotropin and thyrotropin receptors with
extracellular leucine-rich repeats and a G protein-coupled, seven
transmembrane region. Mol Endocrinol 12:18301845[Abstract/Free Full Text]
-
Kobe B, Deisenhofer J 1993 Crystal structure of porcine
ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366:751756[CrossRef][Medline]
-
Kobe B, Deisenhofer J 1994 The leucine-rich repeat: a
versatile binding motif. Trends Biochem Sci 19:415421[CrossRef][Medline]
-
Xie YB, Wang H, Segaloff DL 1990 Extracellular domain of
lutropin/choriogonadotropin receptor expressed in transfected cells
binds choriogonadotropin with high affinity. J Biol Chem 265:2141121414[Abstract/Free Full Text]
-
Tsai-Morris CH, Buczko E, Wang W, Dufau ML 1990 Intronic
nature of the rat luteinizing hormone receptor gene defines a soluble
receptor subspecies with hormone binding activity. J Biol Chem 265:1938519388[Abstract/Free Full Text]
-
Moyle WR, Bernard MP, Myers RV, Marko OM, Strader CD 1991 Leutropin/b-adrenergic receptor chimeras bind choriogonadotropin and
adrenergic ligands but are not expressed at the cell surface. J
Biol Chem 266:1080710812[Abstract/Free Full Text]
-
Braun T, Schofield PR, Sprengel R 1991 Amino-terminal
leucine-rich repeats in gonadotropin receptors determine hormone
selectivity. EMBO J 10:18851890[Abstract]
-
Ji I, Ji TH 1991 Exons 110 of the rat LH receptor encode a
high affinity hormone binding site and exon 11 encodes G-protein
modulation and a potential second hormone binding site. Endocrinology 128:26482650[Abstract]
-
Davis D, Liu X, Segaloff DL 1995 Identification of the sites
of N-linked glycosylation on the follicle-stimulating hormone (FSH)
receptor and assessment of their role in FSH receptor function. Mol
Endocrinol 9:159170[Abstract]
-
Osuga Y, Kudo M, Kaipia A, Kobilka B, Hsueh AJ 1997 Derivation
of functional antagonists using N-terminal extracellular domain of
gonadotropin and thyrotropin receptors. Mol Endocrinol 11:16591668[Abstract/Free Full Text]
-
Ji I, Ji TH 1995 Differential roles of exoloop 1 of the human
follicle-stimulating hormone receptor in hormone binding and receptor
activation. J Biol Chem 270:1597015973[Abstract/Free Full Text]
-
Ryu K-S, Gilchrist RL, Ji I, Kim S-J, Ji TH 1996 Exoloop 3 of
the luteinizing hormone/choriogonadotropin receptor. J Biol Chem 271:73017304[Abstract/Free Full Text]
-
Fernandez LM, Puett D 1996 Lys-583 in the third extracellular
loop of the lutropin/choriogonadotropin receptor is critical for
signaling. J Biol Chem 271:925930[Abstract/Free Full Text]
-
Rajagopalan-Gupta RM, Lamm ML, Mukherjee S, Rasenick MM,
Hunzicker-Dunn M 1998 Luteinizing hormone/choriogonadotropin
receptor-mediated activation of heterotrimeric guanine nucleotide
binding proteins in ovarian follicular membranes. Endocrinology 139:45474555[Abstract/Free Full Text]
-
Rajagopalan-Gupta RM, Rasenick MM, Hunzicker-Dunn M 1997 Luteinizing hormone/choriogonadotropin-dependent, cholera
toxin-catalyzed adenosine 5'-diphosphate (ADP)-ribosylation of the long
and short forms of Gs
and pertussis toxin-catalyzed ADP-ribosylation
of Gi
. Mol Endocrinol 11:538549[Abstract/Free Full Text]
-
Gudermann T, Birnbaumer M, Birnbaumer L 1992 Evidence for dual
coupling of the murine luteinizing hormone receptor to adenylyl cyclase
and phosphoinositide breakdown and Ca+2 mobilization. J Biol Chem 267:44794488[Abstract/Free Full Text]
-
Wang Z, Hipkin RW, Ascoli M 1996 Progressive cytoplasmic tail
truncations of the lutropin-choriogonadotropin receptor prevent
agonist- or phorbol ester-induced phosphorylation, impair agonist-
or phorbol ester-induced desensitization, and enhance
agonist-induced receptor down-regulation. Mol Endocrinol 10:748758[Abstract]
-
Herrlich A, Kuhn B, Grosse R, Schmid A, Schultz G, Gudermann T 1996 Involvement of Gs and Gi proteins in dual coupling of the
luteinizing hormone receptor to adenylyl cyclase and phospholipase C.
J Biol Chem 271:1676416772[Abstract/Free Full Text]
-
Latronico A, Segaloff D 1999 Naturally occurring mutations of
the luteinizing-hormone receptor: lessons learned about reproductive
physiology and G protein-coupled receptors. Am J Hum Genet 65:949958[CrossRef][Medline]
-
Latronico AC, Shinozaki H, Guerra Jr G, Pereira MA, Lemos
Marini SH, Baptista MT, Arnhold IJ, Fanelli F, Mendonca BB, Segaloff DL 2000 Gonadotropin-independent precocious puberty due to luteinizing
hormone receptor mutations in Brazilian boys: a novel constitutively
activating mutation in the first transmembrane helix. J Clin
Endocrinol Metab 85:47994805[Abstract/Free Full Text]
-
Abell AN, Segaloff DL 1997 Evidence for the direct involvement
of transmembrane region six of the lutropin/choriogonadotropin receptor
in activating Gs. J Biol Chem 272:1458614591[Abstract/Free Full Text]
-
Abell AN, McCormick D, Segaloff DL 1998 Certain activating
mutations within helix 6 of the human luteinizing hormone receptor may
be explained by alterations that allow transmembrane regions to
activate Gs. Mol Endocrinol 12:18571869[Abstract/Free Full Text]
-
Latronico AC, Abell AN, Arnhold IJP, Liu X, Lins TSS, Brito
VN, Billerbeck AE, Segaloff DL, Mendonca BB 1998 A unique
constitutively activating mutation in the third transmembrane helix of
the luteinizing hormone receptor causes sporadic male gonadotropin
independent precocious puberty. J Clin Endocrinol Metab 83:24352440[Abstract/Free Full Text]
-
Baldwin JM, Schertler GFX, Unger VM 1997 An alpha-carbon
template for the transmembrane helices in the rhodopsin family of
G-protein-coupled receptors. J Mol Biol 272:144164[CrossRef][Medline]
-
Zhu X, Gilbert S, Birnbaumer M, Birnbaumer L 1994 Dual
signaling potential is common among Gs-coupled receptors and dependent
on receptor density. Mol Pharmacol 46:460469[Abstract]
-
Whaley BS, Yuan N, Birnbaumer L, Clark RB, Barber R 1994 Differential expression of the ß-adrenergic receptor modifies
agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol
Pharmacol 45:481489[Abstract]
-
Latronico AC, Chai Y, Arnhold IJP, Liu X, Mendonca BB,
Segaloff DL 1998 A homozygous microdeletion in helix 7 of the
luteinizing hormone receptor associated with familial testicular and
ovarian resistance is due to both decreased cell surface expression and
impaired effector activation by the cell surface receptor. Mol
Endocrinol 12:442450[Abstract/Free Full Text]
-
Tao Y-X, Abell AN, Liu X, Nakamura K, Segaloff DL 2000 Constitutive activation of G protein coupled receptors as a result of
selective substitution of a conserved leucine residue in transmembrane
helix III. Mol Endocrinol 14:12721282[Abstract/Free Full Text]
-
Shenker A, Laue L, Kosugi S, Merendino Jr JJ, Minegishi T,
Cutler Jr GB 1993 A constitutively activating mutation of the
luteinizing hormone receptor in familial male precocious puberty.
Nature 365:652654[CrossRef][Medline]
-
Jinsi-Parimoo A, Gershengorn MC 1997 Constitutive activity of
native thyrotropin-releasing hormone receptors revealed using a protein
kinase C-responsive reporter gene. Endocrinology 138:14711475[Abstract/Free Full Text]
-
Fanelli F 2000 Theoretical study on mutation-induced
activation of the luteinizing hormone receptor. J Mol Biol 296:13331351[CrossRef][Medline]
-
Samama P, Cotecchia S, Costa T, Lefkowitz RJ 1993 A
mutation-induced activated state of the
ß2-adrenergic receptor: extending the ternary
complex model. J Biol Chem 268:46254636[Abstract/Free Full Text]
-
Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM 1996 Constitutive activation of a single effector pathway: evidence for
multiple activation states of a G protein-coupled receptor. Mol
Pharmacol 49:112122[Abstract]
-
Hwa J, Gaivin R, Porter JE, Perez DM 1997 Synergism of
constitutive activity in
1-adrenergic
receptor activation. Biochemistry 36:633639[CrossRef][Medline]
-
Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox
BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M 2000 Crystal structure of rhodopsin: a G protein-coupled receptor.
Science 289:73945[Abstract/Free Full Text]
-
Lu Z-L, Hulme EC 1999 The functional topography of
transmembrane domain 3 of the m1 muscarinic acetylcholine receptor,
revealed by scanning mutagenesis. J Biol Chem 274:73097315[Abstract/Free Full Text]
-
Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J,
Meng EC, Iiri T, Sheikh SP, Bourne HR 1999 C5a receptor activation:
genetic identification of critical residues in four transmembrane
helices. J Biol Chem 274:1575715765[Abstract/Free Full Text]
-
Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG 1996 Requirement of rigid-body motion of transmembrane helices for light
activation of rhodopsin. Science 274:768770[Abstract/Free Full Text]
-
Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H,
Kobilka BK 1997 Agonists induce conformational changes in transmembrane
domains III and VI of the ß2 adrenoreceptor. EMBO J 16:67376747[Abstract/Free Full Text]
-
Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR 1996 Rhodopsin activation blocked by metal-ion-binding sites linking
transmembrane helices C and F. Nature 383:347350[CrossRef][Medline]
-
Sheikh SP, Vilardarga J-P, Baranski TJ, Lichtarge O, Iiri T,
Meng EC, Nissenson RA, Bourne HR 1999 Similar structures and shared
switch mechanisms of the b2-adrenoceptor and the parathyroid hormone
receptor: Zn(II) bridges between helices III and VI block activation.
J Biol Chem 274:1703317041[Abstract/Free Full Text]
-
Gudermann T, Nichols C, Levy F, Birnbaumer M, Birnbaumer L 1992 Ca2+ mobilization by the LH receptor expressed in
Xenopus oocytes independent of 3',5'-cyclic adenosine
monophosphate formation: evidence for parallel activation of two
signaling pathways. Mol Endocrinol 6:272278[Abstract]
-
Gilchrist RL, Ryu KS, Ji I, Ji TH 1996 The luteinizing
hormone/chorionic gonadotropin receptor has distinct transmembrane
conductors for cAMP and inositol phosphate signals [published erratum
appears in J Biol Chem 1996 Oct 18;271(42):26444]. J Biol
Chem 271:1928319287[Abstract/Free Full Text]
-
Segaloff DL, Ascoli M 1981 Removal of the surface-bound human
choriogonadotropin results in the cessation of hormonal responses in
cultured Leydig tumor cells. J Biol Chem 256:1142011423[Abstract/Free Full Text]
-
Min K-S, Liu X, Fabritz J, Jaquette J, Abell AN, Ascoli M 1998 Mutations that induce constitutive activation and mutations that impair
signal transduction modulate the basal and/or agonist-stimulated
internalization of the lutropin/choriogonadotropin receptor. J
Biol Chem 273:3491134919[Abstract/Free Full Text]
-
Ascoli M, Puett D 1978 Gonadotropin binding and stimulation of
steroidogenesis in Leydig tumor cells. Proc Natl Acad Sci USA 75:99102[Abstract]
-
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR 1989 Site-directed mutagenesis by overlap extension using the polymerase
chain reaction. Gene 77:5159[CrossRef][Medline]
-
Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR 1989 Engineering hybrid genes without the use of restriction enzymes: gene
splicing by overlap extension. Gene 77:6168[CrossRef][Medline]
-
Chen C, Okayama H 1987 High-efficiency transformation of
mammalian cells by plasmid DNA. Mol Cell Biol 7:27452752[Medline]
-
De Lean A, Munson PJ, Rodbard D 1978 Simultaneous analysis of
families of sigmoidal curves: application to bioassay, radioligand
assay and physiological dose-response curves. Am J Physiol
235:E97E102
-
Ascoli M, Pignataro OP, Segaloff DL 1989 The inositol
phosphate/diacylglycerol pathway in MA-10 Leydig tumor cells.
Activation by arginine vasopressin and lack of effect of epidermal
growth factor and human choriogonadotropin. J Biol Chem 264:66746681[Abstract/Free Full Text]
-
Salomon Y 1979 Adenylate cyclase assay. Adv Cyclic Nucleotide
Res 10:3555[Medline]
-
Nakamura K, Lazari MF, Li S, Korgaonkar C, Ascoli M 1999 Role
of the rate of internalization of the agonist-receptor complex on the
agonist-induced down-regulation of the lutropin/choriogonadotropin
receptor. Mol Endocrinol 13:12951304[Abstract/Free Full Text]
-
Ascoli M 1982 Internalization and degradation of
receptor-bound human choriogonadotropin in Leydig tumor cells. Fate of
the hormone subunits. J Biol Chem 257:1330613311[Abstract/Free Full Text]
-
Wiley H, Cunningham D 1982 The endocytotic rate constant. A
cellular parameter for quantitating receptor-mediated endocytosis.
J Biol Chem 257:42224229[Free Full Text]